Biosimilar focus turns to prescribing and uptake

The Australian Rheumatology Association has advised its members to prescribe infliximab by brand name and consider ticking the substitution box, while the Generic and Biosimilar Medicines Association says savings from biosimilars will rely on the successful introduction and adoption of uptake drivers. …